Phagenesis | a medical device company specializing in the treatment of swallowing disorders | successfully closes a $42M Series D financing round led by EQT Life Sciences and Sectoral Asset Management

Phagenesis medical

Denial of Responsibility! Tutti i diritti sono riservati a liberoquotidiano©

Fonte : liberoquotidiano
Phagenesis, a medical device company specializing in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and Sectoral Asset Management (Di lunedì 4 marzo 2024) MANCHESTER, England, March 4, 2024 /PRNewswire/

  Phagenesis, a pioneering UK company which has developed a revolutionary neurostimulation system to treat swallowing dysfunction, has closed a $42M Series D financing all equity investment round. The combined European and United States investment syndicate was led by EQT Life Sciences, and co-led by Sectoral, with new investors British Patient Capital, Northern Gritstone and Aphelion/Cardeation Capital also joining the round. This substantial investment reflects their recognition of the transformative potential of Phagenesis' cutting-edge therapy, Phagenyx®. The Phagenyx® neurostimulation system targets and restores the neurological ...
Leggi tutta la notizia su liberoquotidiano

Phagenesis, a medical device company specializing in the treatment of swallowing disorders, successfully closes a $42M S: MANCHESTER, England, March 4, 2024 /PRNewswire/ -- Phagenesis, a pioneering UK company which has ... Drew Burdon, Partner at EQT Life Sciences, said: "Dysphagia is a severe medical condition that ...europapress.es

Exclusive: Medtech Phagenesis swallows $42M Series D: Motif Neurotech, a developer of brain stimulation devices for depression, in January collected $18.75 million in Series A funding. Cognito Therapeutics, a medical device company using light and sound ...axios

Video di Tendenza
Video Phagenesis medical
© Articolo pubblicato secondo le condizioni dell' Autore.